The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Polypharmacy, potentially inappropriate medications, and chemotherapy-related adverse events among older adults with cancer.
R. J. Maggiore
No relevant relationships to disclose
C. P. Gross
No relevant relationships to disclose
M. Hardt
No relevant relationships to disclose
W. P. Tew
No relevant relationships to disclose
S. G. Mohile
No relevant relationships to disclose
H. D. Klepin
No relevant relationships to disclose
S. M. Lichtman
No relevant relationships to disclose
C. Owusu
No relevant relationships to disclose
A. Gajra
No relevant relationships to disclose
R. Ramani
No relevant relationships to disclose
V. Katheria
No relevant relationships to disclose
J. Brown
No relevant relationships to disclose
R. Jayani
No relevant relationships to disclose
A. Hurria
Consultant or Advisory Role - Amgen; Genentech
Research Funding - Abraxis BioScience